Blood Res.  2020 Sep;55(3):187-189. 10.5045/br.2020.2020102.

Identifying the link between multiple myeloma and neurofibromatosis type I

• Rago A
• Tordi A
• Siniscalchi A
• Andrizzi C
• Campagna S
• Toritto TCd

• KMID: 2507063
• DOI: http://doi.org/10.5045/br.2020.2020102

Abstract

No abstract available.

Figure

• 

  Fig. 1 Magnetic resonance imaging (MRI) revealed a collapse localized at vertebra L1, according to MM involvement.

Reference

1. Hirbe AC, Gutmann DH. 2014; Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 13:834–43. DOI: 10.1016/S1474-4422(14)70063-8. PMID: 25030515.

2. Cimino PJ, Gutmann DH. 2018; Neurofibromatosis type 1. Handb Clin Neurol. 148:799–811. DOI: 10.1016/B978-0-444-64076-5.00051-X. PMID: 29478615.

3. Ferner RE, Gutmann DH. 2013; Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 115:939–55. DOI: 10.1016/B978-0-444-52902-2.00053-9. PMID: 23931823.

4. Rosiñol L, Oriol A, Teruel AI, et al. 2012; Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 120:1589–96. DOI: 10.1182/blood-2012-02-408922. PMID: 22791289.

5. Zengin N, Gönül M, Gül U, et al. 2007; Multiple myeloma in a patient with neurofibromatosis. Am J Hematol. 82:772. DOI: 10.1002/ajh.21012. PMID: 17563076.

6. Accardi F, Marchica V, Mancini C, et al. 2018; Neurofibromatosis type I and multiple myeloma coexistence: a possible link? Hematol Rep. 10:7457. DOI: 10.4081/hr.2018.7457. PMID: 29721253. PMCID: PMC5907645.

7. Chang H, Qi C, Yi QL, Reece D, Stewart AK. 2005; p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 105:358–60. DOI: 10.1182/blood-2004-04-1363. PMID: 15339849.

8. Reynolds RM, Browning GG, Nawroz I, Campbell IW. 2003; Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet. 361:1552–4. DOI: 10.1016/S0140-6736(03)13166-2. PMID: 12737880.

9. Korf BR. 2000; Malignancy in neurofibromatosis type 1. Oncologist. 5:477–85. DOI: 10.1634/theoncologist.5-6-477. PMID: 11110599.

10. Seidl S, Kaufmann H, Drach J. 2003; New insights into the pathophysiology of multiple myeloma. Lancet Oncol. 4:557–64. DOI: 10.1016/S1470-2045(03)01195-1. PMID: 12965277.

11. Rebollo A, Martínez-A C. 1999; Ras proteins: recent advances and new functions. Blood. 94:2971–80. DOI: 10.1182/blood.V94.9.2971. PMID: 10556179.

12. Mangues R, Corral T, Lu S, Symmans WF, Liu L, Pellicer A. 1998; NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity. Oncogene. 17:1705–16. DOI: 10.1038/sj.onc.1202097. PMID: 9796699.

13. Sonneveld P, Avet-Loiseau H, Lonial S, et al. 2016; Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 127:2955–62. DOI: 10.1182/blood-2016-01-631200. PMID: 27002115. PMCID: PMC4920674.

14. Ross FM, Avet-Loiseau H, Ameye G, et al. 2012; Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 97:1272–7. DOI: 10.3324/haematol.2011.056176. PMID: 22371180. PMCID: PMC3409827.

15. Chan NC, Chan NP. 2017; Recurrent cytogenetic abnormalities in multiple myeloma. Methods Mol Biol. 1541:295–302. DOI: 10.1007/978-1-4939-6703-2_23. PMID: 27910031.